Skip to main content

Table 2 Baseline demographic and disease characteristics (overall population)

From: Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data

Characteristica PBO
(n = 646)
CANA 100 mg
(n = 833)
CANA 300 mg
(n = 834)
Sex, n (%)
 Male 334 (52) 408 (49) 404 (48)
 Female 312 (48) 425 (51) 430 (52)
Age, years 56.3 (9.8) 55.9 (10.1) 55.7 (9.5)
Race, n (%)
 White 470 (73) 591 (71) 610 (73)
 Black or African American 28 (4) 43 (5) 48 (6)
 Asian 82 (13) 103 (12) 100 (12)
 Otherb 66 (10) 96 (12) 76 (9)
HbA1c, % 8.0 (0.9) 8.0 (0.9) 8.0 (1.0)
Body weight, kg 89.3 (21.7) 89.8 (22.3) 88.5 (22.0)
Systolic BP, mmHg 128.2 (13.3) 128.0 (12.8) 128.8 (12.8)
eGFR, mL/min/1.73 m2 87.0 (19.8) 88.3 (19.0) 88.8 (18.9)
Duration of T2DM, years 7.5 (6.2) 7.2 (5.8) 7.4 (6.2)
  1. Data have been previously reported [19, 22, 24]
  2. PBO placebo, CANA canagliflozin, BP blood pressure, eGFR estimated glomerular filtration rate, T2DM type 2 diabetes mellitus, SD standard deviation
  3. aData are mean (SD) unless otherwise indicated
  4. bIncludes American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, multiple, other, unknown, and not reported